What is claimed:

- 1. A method for treating heart failure after myocardial infarction in a subject, comprising:
- a) administering an angiotensin II (AT₁) receptor blocker to said subject for a period beginning about the time of myocardial infarction to about ten weeks; and
- b) administering growth hormone beginning about ten weeks after myocardial infarction.
- 2. The method of claim 1, wherein angiotensin II (AT₁) receptor blocker administration is discontinued about 10 weeks after myocardial infarction.
 - 3. The method of daim 1, wherein said AT₁ receptor blocker comprises losartan.
- 4. A method of treating heart failure in a subject following an ischemic event, comprising;
- a) administering an angiotensin II inhibitor to said subject over a period beginning about the time of said ischemic event, and continuing for a period sufficient to substantially permit favorable left ventricular remodeling; and
- b) administering a growth hormone to said subject at a time approximately after said ventricular remodeling period.
- 5. The method of claim 4, wherein administration of said angiotensin II inhibitor is discontinued at about the time growth formone administration begins.
- 6. The method of claim 4, wherein said angiotensin II inhibitor comprises an AT₁ receptor inhibitor.
 - 7. The method of claim 6, wherein said AT_1 receptor inhibitor comprises losartan.
 - 8. The method of claim 4, wherein said growth hormone is human growth hormone.
- 9. The method of claim 4, wherein said angiotensin II inhibitor is administered beginning within seven days of said is chemic event.
- 10. The method of claim 9, wherein said angiotensin II inhibitor is administered for about 8 to about 12 weeks.
- 11. The method of claim 10, wherein said angiotensin II inhibitor is administered for about 10 weeks.
- 12. The method of claim 9, wherein said growth hormone is administered for about one to about three weeks.
- 13. The method of claim 4, wherein said growth hormone is administered for about two weeks.

- 14. The method of claim 4, wherein said angiotensin II inhibitor is administered at a reduced dosage after said ventricular remodeling period.
- 15. The method of claim 14, wherein said reduced dosage is less than about one half the dosage prior to the end of said wentricular remodeling period.
 - 16. The method of claim 4, wherein steps a) and b) are repeated.